Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
CNTX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Context Therapeutics Inc.NASDAQ: CNTX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $2.33M rose 12.7% year over year, ahead of the +9.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 18.6% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +8.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.33M+18.6% QoQ
- Last fiscal yearDec 2025
- $7.85M+8.6% YoY
- LTMMar 2026
- $8.11M+9.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +12.7% | -100.0% | -112.7 pp |
| 1 year | +8.6% | -100.0% | -108.6 pp |
| 3-year CAGR | +0.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 7.85M USD
- Year-over-year change
- +8.6%
- 4-year CAGR
- +21.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.85M | +8.6% |
| FY2024 | 2024-12-31 | 7.22M | -0.9% |
| FY2023 | 2023-12-31 | 7.29M | -6.4% |
| FY2022 | 2022-12-31 | 7.79M | +114.4% |
| FY2021 | 2021-12-31 | 3.63M | — |
Selling, General & Admin vs competitors
How CNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9.0% is the 2nd highest of 11, against a peer median of -18.3%.
- Over three fiscal years its annual growth of +0.2% compares with a peer median of -6.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $38.15M USD | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $24.75M USD | -6.4% | -9.4% | 347.5% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $23.29M USD | -40.2% | -9.5% | — |
IMAImageneBio Inc | LTM Mar 2026 | $21.2M USD | -9.1% | -2.3% | — |
| FY2025 | $20.34M USD | +5.8% | -0.8% | 31781.3% | |
| LTM Mar 2026 | $17.37M USD | -6.9% | -4.3% | 1736.5% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $15.32M USD | -41.8% | +90.0% | — |
| LTM Mar 2026 | €14.24M EUR | -27.6% | +7.0% | 48538.7% | |
| LTM Mar 2026 | $8.48M USD | +21.4% | -17.7% | — | |
| LTM Mar 2026 | $8.11M USD | +9.0% | +0.2% | — | |
| LTM Mar 2026 | $7.9M USD | -34.1% | -17.0% | 5897.0% | |
| Peer median (excluding CNTX) | — | -18.3% | -6.9% | 3816.8% | |
Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.81M | 7.09M | 17.78M | 22.7M | 31.86M |
| Selling, General & Admin | 3.63M | 7.79M | 7.29M | 7.22M | 7.85M |
| Operating Expenses | 10.53M | 15.38M | 25.07M | 29.92M | 39.7M |
| Depreciation & Amortization | 0 | 9.27K | 12.04K | 10.88K | 16.25K |
| EBITDA | (7.44M) | (14.87M) | (23.95M) | (26.71M) | (36.11M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (10.53M) | (15.38M) | (25.07M) | (29.92M) | (39.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 64 | 547.27K | 1.16M | 3.2M | 3.38M |
| Interest Expense | 64.24K | 547.27K | 0 | 0 | 0 |
| Other Income / Expenses | 68.95K | 545.26K | 1.11M | 3.2M | 3.58M |
| Income Before Tax | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.69) | (0.93) | (1.50) | (0.46) | (0.38) |
| EPS (Diluted) | (3.69) | (0.93) | (1.50) | (0.46) | (0.38) |
| Weighted Avg Shares | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M |
| Weighted Avg Shares (Diluted) | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M |
Context Therapeutics Inc.
NASDAQ:CNTX
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.